DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mast-Cell Stabilizing Effects of Olopatadine

Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Allergic Conjunctivitis

Intervention: Olopatadine (generic name) (Drug)

Phase: Phase 4

Status: Completed

Sponsored by: Alcon Research

Official(s) and/or principal investigator(s):
Terry Wiernas, Study Director, Affiliation: Alcon Research


To assess the effects of olopatadine of the release of mast cell histamine

Clinical Details

Official title: Mast-Cell Stabilizing Effects of Olopatadine

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Primary outcome: Tear histamine

Secondary outcome: Tear cytology, subject evaluation of ocular itching, investigators evaluation of ocular redness


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Asymptomatic and not using any topical or systemic medication

Exclusion Criteria:

- Age

Locations and Contacts

Padova Site, Padova, Italy
Additional Information

Starting date: October 2006
Last updated: January 4, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017